candesartan cilexetil has been researched along with Coronary Restenosis in 2 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The AACHEN trial was a double-blind, randomized, placebo-controlled clinical multicenter trial to evaluate the effects of candesartan cilexetil on intimal hyperplasia after coronary stent implantation." | 9.12 | A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation. ( Büttner, HJ; Daniel, W; Drexler, H; Figulla, HR; Fischer, D; Hanrath, P; Hoffmann, R; Klues, HG; Motz, W; Mügge, A; Ortlepp, JR; Radke, PW; Reifart, N; Schaefers, K; Schmeisser, A; Silber, S, 2006) |
| " The AACHEN trial was a double-blind, randomized, placebo-controlled clinical multicenter trial to evaluate the effects of candesartan cilexetil on intimal hyperplasia after coronary stent implantation." | 5.12 | A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation. ( Büttner, HJ; Daniel, W; Drexler, H; Figulla, HR; Fischer, D; Hanrath, P; Hoffmann, R; Klues, HG; Motz, W; Mügge, A; Ortlepp, JR; Radke, PW; Reifart, N; Schaefers, K; Schmeisser, A; Silber, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yoshida, O | 1 |
| Hirayama, H | 1 |
| Nanasato, M | 1 |
| Watanabe, T | 1 |
| Murohara, T | 1 |
| Radke, PW | 1 |
| Figulla, HR | 1 |
| Drexler, H | 1 |
| Klues, HG | 1 |
| Mügge, A | 1 |
| Silber, S | 1 |
| Daniel, W | 1 |
| Schmeisser, A | 1 |
| Reifart, N | 1 |
| Motz, W | 1 |
| Büttner, HJ | 1 |
| Fischer, D | 1 |
| Ortlepp, JR | 1 |
| Schaefers, K | 1 |
| Hoffmann, R | 1 |
| Hanrath, P | 1 |
2 trials available for candesartan cilexetil and Coronary Restenosis
| Article | Year |
|---|---|
The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Benzimidaz | 2005 |
A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Coronary Angiogra | 2006 |